Increased disease control with Roche's Ocrevus in MS, analyses show

14 September 2016
2019_biotech_test_vial_discovery_big

Swiss pharma major Roche (ROG: SIX) has shared the results of new analyses of three Ocrevus (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

Ocrevus increased disease control in patients with RMS and PPMS in separate post-hoc analyses which are being presented at this week’s European Committee for Treatment and Research in Multiple Sclerosis.

In these analyses, two composite endpoints measured disease control using a combination of clinical and MRI outcomes, namely no evidence of disease activity (NEDA) in patients with RMS and no evidence of progression (NEP) in patients with PPMS. These composite endpoints are emerging as new treatment targets.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology